A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs Cefepime/taniborbactam (Primary) ; Meropenem
- Indications Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Therapeutic Use
- Acronyms CERTAIN-2
- Sponsors VenatoRx Pharmaceuticals
- 30 Oct 2024 Planned End Date changed from 1 Sep 2027 to 1 Dec 2027.
- 30 Oct 2024 Planned primary completion date changed from 1 Mar 2027 to 1 Jun 2027.
- 30 Oct 2024 Planned initiation date changed from 1 Oct 2024 to 1 Jun 2025.